Navigation Links
InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
Date:2/16/2011

BRISBANE, Calif., Feb. 16, 2011 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the fourth quarter and full year ended December 31, 2010.

InterMune reported net income for the fourth quarter of 2010 of $206.1 million, or $3.34 per diluted share, compared with a net loss of $28.6 million, or $0.62 per diluted share, in the fourth quarter of 2009. Net income for the full year 2010 was $122.4 million, or $2.13 per diluted share, compared with a net loss of $116.0 million, or $2.62 per diluted share, in 2009.

Results for the fourth quarter and full year 2010 include proceeds of $175.0 million from the sale of danoprevir in October 2010 and the accelerated recognition of approximately $57.3 million of remaining deferred revenue in connection with the termination of the 2006 Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd. (Roche) collaboration agreement.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "Our financial results in 2010 were driven by the sale of our rights to danoprevir to Roche, which enabled us to end the year with $295 million in cash and cash equivalents and provided the financial resources to independently maximize the world-wide value of pirfenidone. In December of 2010 we announced the adoption of a positive opinion by European regulatory authorities for the marketing authorization of Esbriet™ (pirfenidone) and we expect Esbriet to soon become the first therapy approved for the treatment of IPF patients in Europe. Regarding the U.S., we announced in January of 2011 our plan to conduct a Phase 3 study toward the potential U.S. FDA approval of Esbriet for the more than 100,000 Americans who suffer from IPF."

Recent Clinical Development, Business Highlights and Upcoming MilestonesEsbriet™ (pirfenidone):

  • InterMune reported on Dec
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
    2. InterMune Announces Start of Phase 1b Trial of ITMN-191
    3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
    4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
    5. InterMune Announces Progress on Pirfenidone in IPF
    6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
    7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
    8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
    9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
    10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
    11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... 2015  IDEXX Laboratories, Inc. (NASDAQ: IDXX ) ... of $413 million, an increase of 6% compared to ... the US dollar reduced reported revenue growth by 7%. ... was 11%, supported by strong growth in the Companion ... ("EPS") was $0.60 for the quarter, an increase of ...
    (Date:7/29/2015)... 2015  Astellas today announced topline results from ... and safety of intravenous (IV) and oral isavuconazole, ... for adults with candidemia and other invasive ... that the trial did not meet its primary ... isavuconazole-treated patients at the end of IV therapy ...
    (Date:7/29/2015)... , July 29, 2015  Unilife Corporation ("Unilife" ... UNS), a developer, manufacturer and supplier of injectable drug ... financing strategy that provides the Company with flexibility and ... Unilife has signed an equity purchase agreement for ... LLC ("LPC"), a Chicago -based institutional ...
    Breaking Medicine Technology:IDEXX Laboratories Announces Second Quarter Results 2IDEXX Laboratories Announces Second Quarter Results 3IDEXX Laboratories Announces Second Quarter Results 4IDEXX Laboratories Announces Second Quarter Results 5IDEXX Laboratories Announces Second Quarter Results 6IDEXX Laboratories Announces Second Quarter Results 7IDEXX Laboratories Announces Second Quarter Results 8IDEXX Laboratories Announces Second Quarter Results 9IDEXX Laboratories Announces Second Quarter Results 10IDEXX Laboratories Announces Second Quarter Results 11IDEXX Laboratories Announces Second Quarter Results 12IDEXX Laboratories Announces Second Quarter Results 13IDEXX Laboratories Announces Second Quarter Results 14IDEXX Laboratories Announces Second Quarter Results 15IDEXX Laboratories Announces Second Quarter Results 16IDEXX Laboratories Announces Second Quarter Results 17IDEXX Laboratories Announces Second Quarter Results 18IDEXX Laboratories Announces Second Quarter Results 19IDEXX Laboratories Announces Second Quarter Results 20IDEXX Laboratories Announces Second Quarter Results 21IDEXX Laboratories Announces Second Quarter Results 22IDEXX Laboratories Announces Second Quarter Results 23IDEXX Laboratories Announces Second Quarter Results 24IDEXX Laboratories Announces Second Quarter Results 25IDEXX Laboratories Announces Second Quarter Results 26IDEXX Laboratories Announces Second Quarter Results 27IDEXX Laboratories Announces Second Quarter Results 28IDEXX Laboratories Announces Second Quarter Results 29Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4
    ... - Trial Results Confirm Efficacy for Population ... N.J. and EMERYVILLE, Calif., May 16 ,Bayer ... ONXX ) today announced that Nexavar(R) ... percent (HR=0.68;,p-value=0.014) in patients in the Asia-Pacific ...
    ... Ovarian ... Cancers -, - Company ... SOUTH SAN FRANCISCO, Calif., May 15 Poniard,Pharmaceuticals, Inc. (Nasdaq: ... will present data from three,clinical trials of picoplatin, in various tumor types ...
    Cached Medicine Technology:Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 4Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 5
    (Date:7/30/2015)... ... ... On July 23rd Clay Today Online reported the state of Florida ... system, which has amassed largely enough throughout the years. Florida is the third state ... recent reduction of non violent drug offender’s prison sentences, Florida is beginning to take ...
    (Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Gummy ... including lip lowering, gum contouring and surgery, as well as the patented gum depigmentation ... that has made him popular with many patients from around the world. , “Like ...
    (Date:7/30/2015)... ... July 30, 2015 , ... New research finds some distinct differences in the ... on the Surviving Mesothelioma website. , Researchers with the National Institutes of ... 12,000 cases of mesothelioma occurring between 1990 and 2010. Two percent of these cases ...
    (Date:7/30/2015)... NEW ORLEANS (PRWEB) , ... July 30, 2015 , ... ... wellbeing and take charge of their health in his new self-help book, “ Consciously ... , Llanos’ new book promotes a simple message: “If we take responsibility for ourselves, ...
    (Date:7/30/2015)... ... July 30, 2015 , ... After a three year trial designed to ... commonly known as the “bionic eye,” researchers have determined the trial to be a ... patients facing or already affected by complete vision loss as a result of Retinitis ...
    Breaking Medicine News(10 mins):Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 3Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2
    ... support to the House of Commons vote to impose a ban ... ,A team of researchers measured the air quality, using a portable ... areas where smoking was permitted. The study revealed that the quality ... This, when inhaled, would cause harm to the health. ...
    ... An outbreak of cholera was first reported in the Luanda ... nearly 652 cases of cholera// and 22 cholera related deaths ... the latest health report published by the World Health Organization, ... reported over the past 24 hours. 8 municipalities have been ...
    ... 11-year-olds had taken a Class A drug, such as cocaine, ... taken hard drugs. There is a rise in illegal drug ... cocaine which has created a lot of trouble for the ... England's 3.4 million secondary pupils. Despite undertaking multi-million-pound campaigns such ...
    ... an agricultural engineer has developed a technique which uses ... serum albumin (HSA) from tobacco plants. HSA is an ... therapeutic needs. ,It is mainly used to ... attacks. It is used for haemorrhages, burns, surgical operations ...
    ... joined forces to create an Internet-based training programme ... degrees while continuing to work. ,The ... March, will create online courses for vets unable ... network. ,African vets urgently need extra ...
    ... European Breast Cancer Conference (EBCC-5) have called that patients should ... in the field. Doctors and patient groups said that women ... like Herceptin that could help prolong their survival and well ... and radiation therapy are available to women in the United ...
    Cached Medicine News:Health News:Alternate ways to produce HAS from tobacco plants 2
    ... The SmartCycler System is a rapid, real-time ... prepared biological samples. By automating much of ... site individually programmable, it is the fastest, ... now on the market. The SmartCycler delivers ...
    ... The LightCycler 2.0 System is the newest ... Science. This new instrument offers six detection ... 560, 610, 640, 670, and 710nm. Perform ... by air and working with glass capillaries. ...
    Mx3000P instrument, desktop computer, Mx3000P software package, user's manual, one Brilliant QPCR Reagent of your choice, and custom filter wheel with 4 filters chosen from: FAM/SYBR Green I, TET, HE...
    ... Stratagene delivers a new standard in QPCR ... This new system offers superior performance, more ... unit, Computer system - with Windows 98SE ... Keyboard, Mouse, Premier Sound Speakers, Surge Protector ...
    Medicine Products: